The reason for developing agents comprising a bombesin-derived agent (targeting the GRPR) and a Glu-urea-Lys or Glu-urea-Glu structure motive (addressing the PSMA) for imaging of prostate carcinoma (PCa) results from the changes of the receptor statuses during progression of the disease. The gene discussed is GRPR; the disease is prostate carcinoma.